Vaccentis

Vaccentis is a health care startup with a focus on developing immuno-oncology vaccines utilizing its autologous tumor vaccine technology platform. The company was founded in 2006 and is currently in the late stage development of an autologous tumor vaccine for Renal Cell Carcinoma. Their medical division is dedicated to developing clinically proven products that have been shown to maintain remission and alleviate disease. Their flagship product, the VCC-001 cancer vaccine, has shown promising Phase III data in Renal Cell Cancer, demonstrating clinical effect and high tolerance, particularly significant as there are few current treatment options for this disease. Moreover, the VCC-001 cancer vaccine platform holds significant potential in treating metastatic renal cell, colon, and pancreatic cancers. As of now, there is no public information available about their last investment or the investors involved.